InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
11 hedge funds and large institutions have $227K invested in InVivo Therapeutics Holdings Corp in 2020 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
58% more capital invested
Capital invested by funds: $144K → $227K (+$83K)
22% more funds holding
Funds holding: 9 → 11 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$87.3K |
| 2 |
Two Sigma Advisers
New York
|
+$46.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$35.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$34.5K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$5.68K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
-$116K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4.93K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $90K | +$87.3K | +4,459 | New |
|
|
2
Two Sigma Advisers
New York
| $48K | +$46.3K | +2,364 | New |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $37K | +$35.8K | +1,831 | New |
|
|
4
Geode Capital Management
Boston,
Massachusetts
| $35K | +$34.5K | +1,763 | New |
|
|
5
Northern Trust
Chicago,
Illinois
| $16K | +$5.68K | +290 | +57% |
|
6
BlackRock
New York
| $1K | – | – | – |
|
|
WS
7
Wedbush Securities
Los Angeles,
California
| – | -$116K | -3,260 | Closed |
|
|
8
UBS Group
Zurich,
Switzerland
| – | -$4.93K | -252 | Closed |
|
|
9
Bank of America
Charlotte,
North Carolina
| – | -$20 | -1 | -50% |
|
10
Wells Fargo
San Francisco,
California
| – | +$98 | +5 | +500% |
|
NVIV Hedge Fund Activity: Q4 2020 in Review
11 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q4 2020, worth a combined $227K — up 58% from $144K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NVIV positions and 2 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $87.3K. The largest seller was Wedbush Securities, exiting entirely with an estimated $116K sold.
- 11 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q4 2020, up from 9 in Q3 2020.
- Funds reported $227K of InVivo Therapeutics Holdings Corp stock for Q4 2020, up 58% quarter-over-quarter.
- 4 funds opened new InVivo Therapeutics Holdings Corp positions in Q4 2020 and 2 closed out, a net change of +2 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q4 2020 was Renaissance Technologies, an estimated $87.3K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q4 2020 was Wedbush Securities, an estimated $116K sold.
Based on aggregated 13F filings for Q4 2020.